We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.99B
AUM Growth
+$404M
Cap. Flow
-$70.3M
Cap. Flow %
-2.35%
Top 10 Hldgs %
40.51%
Holding
78
New
15
Increased
15
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48M
3
ABVX
Abivax
ABVX
+$43.8M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$42.2M
5
TRML
Tourmaline Bio
TRML
+$36.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
2
GPCR icon
Structure Therapeutics
GPCR
+$92.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$75.9M
4
IMVT icon
Immunovant
IMVT
+$66.2M
5
NVCR icon
NovoCure
NVCR
+$40.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$532M
$46.3M 1.55%
2,284,372
-493,735
-18% -$6.5M
ABVX
27
Abivax
ABVX
$10.8B
$46M 1.54%
+4,297,438
New +$43.8M
RAPT
28
DELISTED
RAPT Therapeutics
RAPT
$44.6M 1.49%
224,246
+36,746
+20% +$4.55M
ANAB icon
29
AnaptysBio
ANAB
$1.58B
$43.6M 1.46%
2,036,990
+691,177
+51% +$11.9M
IMVT icon
30
Immunovant
IMVT
$7.93B
$42.1M 1.41%
1,000,000
-1,797,955
-64% -$66.2M
SYRE icon
31
Spyre Therapeutics
SYRE
$8.54B
$42M 1.4%
+1,952,760
New +$26.9M
OCUL icon
32
Ocular Therapeutix
OCUL
$1.79B
$41.2M 1.37%
+9,230,769
New +$27.3M
ACLX
33
DELISTED
Arcellx
ACLX
$40.2M 1.34%
+725,145
New +$32.7M
TERN
34
DELISTED
Terns Pharmaceuticals
TERN
$39.6M 1.32%
6,100,000
+100,000
+2% +$529K
SLN
35
Silence Therapeutics
SLN
$495M
$33.9M 1.13%
1,951,580
– –
ORTX
36
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$33.6M 1.12%
2,041,670
– –
NUVL
37
DELISTED
Nuvalent
NUVL
$33.1M 1.11%
+450,000
New +$27.8M
ANIP icon
38
ANI Pharmaceuticals
ANIP
$1.8B
$33.1M 1.1%
600,000
+200,000
+50% +$11M
NRIX icon
39
Nurix Therapeutics
NRIX
$2.41B
$30.9M 1.03%
2,997,830
– –
EWTX icon
40
Edgewise Therapeutics
EWTX
$4.13B
$27.8M 0.93%
2,537,176
-212,824
-8% -$1.49M
OLMA icon
41
Olema Pharmaceuticals
OLMA
$1B
$27.1M 0.9%
1,930,894
– –
DYN icon
42
Dyne Therapeutics
DYN
$4.7B
$26.6M 0.89%
2,000,000
-403,672
-17% -$3.94M
AGEN
43
Agenus
AGEN
$312M
$26.2M 0.88%
1,584,877
– –
CYTK icon
44
Cytokinetics
CYTK
$10.5B
$24.1M 0.81%
+288,949
New +$10.5M
AGIO icon
45
Agios Pharmaceuticals
AGIO
$1.79B
$23.7M 0.79%
1,062,881
+640,634
+152% +$14.4M
RPTX
46
DELISTED
Repare Therapeutics
RPTX
$21.8M 0.73%
2,992,731
-75,000
-2% -$420K
SRRK icon
47
Scholar Rock
SRRK
$5.67B
$19M 0.64%
1,011,829
+657,974
+186% +$8.18M
PRTA icon
48
CALL
Prothena Corp
PRTA
$425M
$18.2M 0.61%
+500,000
New +$19.2M
GPCR icon
49
Structure Therapeutics
GPCR
$3.41B
$12.2M 0.41%
300,000
-1,615,000
-84% -$92.6M
ZURA icon
50
Zura Bio
ZURA
$516M
$11.8M 0.39%
2,523,000
– –
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Deep Track Capital held 78 positions worth $2.99B, up 16% from $2.59B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital's Q4 2023 filing shows 15 new, 15 increased, 16 reduced and 18 closed positions. Its largest new stake was argenx: 300,000 shares worth $114M. The largest sale was Jazz Pharmaceuticals, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q4 2023 buy was argenx: 300,000 shares worth $114M.
  • Deep Track Capital added most to Guardant Health in Q4 2023, an estimated $24.9M increase.
  • Deep Track Capital's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $136M.
  • Deep Track Capital fully exited NovoCure in Q4 2023, selling an estimated $40.4M.
  • Deep Track Capital's ten largest holdings make up 41% of its $2.99B portfolio in Q4 2023.
  • Deep Track Capital opened 15 new positions and closed 18 in Q4 2023.
  • Deep Track Capital's portfolio value rose 16% quarter-over-quarter to $2.99B.

Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.